References
- Mills SE, Carter D, Greenson JK, Ruter VE, Stoler MH. editors. Sternberg's diagnostic surgical pathology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010. p 1901.
- Melicow MM, Pachter MR. Endometrial carcinoma of prostatic utricle (uterus masculinus). Cancer 1967;20:1715.
- Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer 1986;57:111–19.
- Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol 1999;23:781–5.
- Lee TK, Miller JS, Epstein JI. Rare histological patterns of prostatic ductal adenocarcinoma. Pathology 2010;42:319–24.
- Millar EK, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: clinicopathological study of 16 cases. Histopathology 1996;29:11–19.
- Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathological, and ultrastructural findings. Am J Surg Pathol 1985;9:595–609.
- Christensen WN, Steinberg G, Walsh PC, Epstein JI. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer 1991;67:2118.
- Copeland JN, Amin MB, Humphrey PA, Tamboli P, Ro JY, Gal AA. The morphologic spectrum of metastatic prostate adenocarcinoma to the lung: special emphasis on histologic features overlapping with other pulmonary neoplasms. Am J Clin Pathol 2002;117:552–7.
- Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Prostate carcinoma with testicular or penile metastases: clinical, pathologic, and immunohistochemical features. Cancer 2002;94:2610–17.
- Egevad L. Reproducibility of Gleason grading of prostate cancers can be improved by the use of reference images. Urology 2001;57:291–5.
- Amin M, Boccon-Gibod L, Egevard L, Epstein JI, Humphrey PA, Mikuz G, Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 2005;216:20–33.
- Epstein JI. Prostatic ductal adenocarcinoma: a mini review. Med Princ Pract 2010;19:82–5.
- Tabár L, Tot T, Dean PB. Breast cancer: the art and science of early detection with mammography. Vol I Perception, interpretation, histopathologic correlation. Stuttgart: Thieme; 2005. p 405–38.
- Kastendieck H, Altenähr E, Hüsselmann H, Bressel M. Carcinoma and dysplastic lesion of the prostate. A histomorphological analysis of 50 total prostatectomies by step-section technique. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1976;88:33–54.
- Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540–5.
- Morgan TD, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol 2010;184:2303–7.
- Samaratunga H, Duffy D, Yaxley J, Delahunt B. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol 2010;41:281–5.
- Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 1999;23:1471.
- Gong Y, Caraway N, Stewart J, Staerkel G. Metastatic ductal adenocarcinoma of the prostate. Cytologic features and clinical findings. Am J Clin Pathol 2006;126:302–9.
- Amin A, Epstein JI. Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of ductal component and associated grade of acinar adenocarcinoma. Am J Surg Pathol 2011;35:615–19.
- Tulunay O, Orhan D, Baltaci S, Gögus C, Muftuoglu YZ. Prostatic ductal adenocarcinoma showing bcl-2 expression. Int J Urol 2004;11:805–8.
- Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002;117:471–2.